NCT01013324 2016-06-03
Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma
Sanofi
Phase 2 Completed
Clinical Trials
12 trialsNCT01042925 2016-06-03
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Sanofi
Phase 1/2 Completed
NCT01082068 2016-06-03
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Sanofi
Phase 1/2 Completed
NCT01943838 2016-04-22
A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma
Sanofi
Phase 1 Completed
NCT01357330 2016-04-01
Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors
Sanofi
Phase 1 Completed
NCT00704392 2015-08-20
Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors
Exelixis
Phase 1 Withdrawn
NCT01392924 2014-12-03
Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors
Sanofi
Phase 1 Completed
NCT01436565 2014-06-13
A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
Sanofi
Phase 1 Completed
NCT00756847 2013-04-10
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
Sanofi
Phase 1 Completed
NCT00486135 2013-02-01
Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma
Sanofi
Phase 1 Completed
NCT01240460 2012-07-27
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection
Sanofi
Phase 1 Completed
NCT00692640 2012-03-23
Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors
Sanofi
Phase 1 Completed